CMN Weekly (13 December 2024) - Your Weekly CRISPR...
CMN Weekly
Dec. 13, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Fate Therapeutics
General information
Main focus: Allogeneic natural killer cell therapies
Company stage: Clinical
Diseases: Acute myleoid leukaemia (AML), B-cell lymphoma (BCL), chronic lymphocytic leukaemia (CLL), multiple myeloma (MM), solid tumours
Genome editing tool: CRISPR-Cas9
Funding stage: Public (NASDAQ:FATE)
Location: San Diego, CA, USA
Website: https://fatetherapeutics.com/
Pipeline: https://fatetherapeutics.com/pipeline/
Partners: Janssen Pharmaceuticals, Ono Pharma, Inscripta
Fate Therapeutics is a publicly-traded, clinical-stage, biopharmaceutical company mainly focusing on the development of first-in-class cellular immunotherapies. The company applies an in house iPSC and gene-editing platform to develop T- and natural killer cell therapies targeting blood cancers and solid tumours.
Tags
Related News and Updates
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
Relapsed or Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia, (NCT04245722)
Sponsors:
Fate Therapeutics
Sponsors:
Fate Therapeutics
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
